VEGF-C/Flt4-L[Biotin], His & Avi, Human
VEGF-C/Flt4-L[Biotin], His & Avi, Human

Immobilized VEGF-C/Flt4-L[Biotin], His & Avi, Human, His Tag at 1 μg/ml (100 μl/Well) on streptavidin(5 μg/ml) precoated plate. Dose response curve for Human VEGF R3, hFc Tag with the EC50 of 7.8 ng/ml determined by ELISA.

VEGF-C/Flt4-L[Biotin], His & Avi, Human

VEGF-C/Flt4-L[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced (R) condition. The purity is greater than 95%.

VEGF-C/Flt4-L[Biotin], His & Avi, Human

the lymphangiogenic factors vascular endothelial growth factor C (VEGFC) and VEGFD are cleaved by thrombin and plasmin, serine proteases generated during hemostasis and wound healing. Genetic studies reveal that platelet enhancement of lymphatic growth after wounding is dependent on the release of VEGFC, but not VEGFD, a finding consistent with high expression of VEGFC in both platelets and avian thrombocytes.
Z04644
¥123,118.00

Ask us a question
Product Introduction
Species Human
Protein Construction
VEGF-C/Flt4-L (Thr103-Arg227)
Accession # Q6FH59		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized VEGF-C/Flt4-L[Biotin], His & Avi, Human at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml) can bind Human VEGF R3, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 17.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 23-30 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 50mM MES, 150mM NaCl (pH 6.0).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 50mM MES, 150mM NaCl (pH 6.0).
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • VEGF-C/Flt4-L[Biotin], His & Avi, Human
    • VEGF-C/Flt4-L[Biotin], His & Avi, Human

    Immobilized VEGF-C/Flt4-L[Biotin], His & Avi, Human, His Tag at 1 μg/ml (100 μl/Well) on streptavidin(5 μg/ml) precoated plate. Dose response curve for Human VEGF R3, hFc Tag with the EC50 of 7.8 ng/ml determined by ELISA.

  • VEGF-C/Flt4-L[Biotin], His & Avi, Human
    • VEGF-C/Flt4-L[Biotin], His & Avi, Human

    VEGF-C/Flt4-L[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced (R) condition. The purity is greater than 95%.


Background
Target Background the lymphangiogenic factors vascular endothelial growth factor C (VEGFC) and VEGFD are cleaved by thrombin and plasmin, serine proteases generated during hemostasis and wound healing. Genetic studies reveal that platelet enhancement of lymphatic growth after wounding is dependent on the release of VEGFC, but not VEGFD, a finding consistent with high expression of VEGFC in both platelets and avian thrombocytes.
Synonyms VEGFC; VEGFc; Flt4-L; VRP; VEGF-C

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.